MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone301-251-5172
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.12 million
Profitability
Miscellaneous
Employees364
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
MacroGenics (NASDAQ:MGNX) Frequently Asked Questions
What is MacroGenics' stock symbol?
MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."
How were MacroGenics' earnings last quarter?
MacroGenics Inc (NASDAQ:MGNX) posted its earnings results on Wednesday, July, 31st. The biopharmaceutical company reported ($0.65) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.31. The biopharmaceutical company earned $10.59 million during the quarter, compared to analysts' expectations of $17.58 million. MacroGenics had a negative net margin of 273.47% and a negative return on equity of 54.52%. View MacroGenics' Earnings History.
When is MacroGenics' next earnings date?
What price target have analysts set for MGNX?
11 brokers have issued 12 month price objectives for MacroGenics' shares. Their predictions range from $19.00 to $50.00. On average, they expect MacroGenics' stock price to reach $32.76 in the next twelve months. This suggests a possible upside of 191.4% from the stock's current price. View Analyst Price Targets for MacroGenics.
What is the consensus analysts' recommendation for MacroGenics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MacroGenics.
What are Wall Street analysts saying about MacroGenics stock?
Here are some recent quotes from research analysts about MacroGenics stock:
- 1. According to Zacks Investment Research, "MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland. " (10/3/2019)
- 2. HC Wainwright analysts commented, "Our 12-month, $39 price target for shares of MacroGenics is based on a 12-year DCF-driven sum-of-the-parts analysis. Our DCF is driven by: beta of 1.8, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.5%, and tax rate of 15% beginning in FY 2027. (18%), flotetuzumab (16%) together represent our full target. Risks potentially incurred investing in this stock include: clinical and development, financial, regulatory and reimbursement, and commercial." (5/2/2019)
Has MacroGenics been receiving favorable news coverage?
News headlines about MGNX stock have been trending negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MacroGenics earned a news impact score of -2.8 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for MacroGenics.
Are investors shorting MacroGenics?
MacroGenics saw a decline in short interest in September. As of September 30th, there was short interest totalling 4,110,000 shares, a decline of 10.8% from the August 30th total of 4,610,000 shares. Based on an average daily trading volume, of 417,200 shares, the days-to-cover ratio is currently 9.9 days. Currently, 9.4% of the company's stock are short sold. View MacroGenics' Current Options Chain.
Who are some of MacroGenics' key competitors?
Some companies that are related to MacroGenics include PTC Therapeutics (PTCT), BridgeBio Pharma (BBIO), Amicus Therapeutics (FOLD), Cambrex (CBM), Ligand Pharmaceuticals (LGND), Zai Lab (ZLAB), Intercept Pharmaceuticals (ICPT), Xencor (XNCR), Agios Pharmaceuticals (AGIO), Portola Pharmaceuticals (PTLA), Akcea Therapeutics (AKCA), Prestige Consumer Healthcare (PBH), Zogenix (ZGNX), Deciphera Pharmaceuticals (DCPH) and Apellis Pharmaceuticals (APLS).
What other stocks do shareholders of MacroGenics own?
Who are MacroGenics' key executives?
MacroGenics' management team includes the folowing people:
- Dr. Scott Koenig, CEO, Pres & Director (Age 67)
- Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)
- Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)
- Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)
- Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57)
How do I buy shares of MacroGenics?
Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is MacroGenics' stock price today?
One share of MGNX stock can currently be purchased for approximately $11.24.
How big of a company is MacroGenics?
MacroGenics has a market capitalization of $549.56 million and generates $60.12 million in revenue each year. The biopharmaceutical company earns $-171,450,000.00 in net income (profit) each year or ($4.19) on an earnings per share basis. MacroGenics employs 364 workers across the globe.View Additional Information About MacroGenics.
What is MacroGenics' official website?
How can I contact MacroGenics?
MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172.
MarketBeat Community Rating for MacroGenics (NASDAQ MGNX)
MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote "Outperform" if you believe MGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
